158
Participants
Start Date
October 31, 2007
Primary Completion Date
March 31, 2009
Study Completion Date
April 30, 2009
Radezolid
300 mg/day, orally for 7-10 days
Radezolid
450 mg/day orally for 7-10 days
Radezolid
900 mg/day orally for 7-10 days
eStudySite, San Diego
Olive View- UCLA Center, Dept. Emergency Medicine, Sylmar
Wayne State University School of Medicine/Detroit Receiving Hospital, Detroit
Arnold Markowitz, MD, Keego Harbor
Mercury Street Medical Group, LLC, Butte
Dr. John Bernard, Belvidere
University of Medicine & Dentistry of New Jersey, School of Osteopathic Medicine (UMDNJ-SOM), Cherry Hill
Warminster Medical Associates, P.C., Warminster
Ronald Collette, MD, Burnaby
The Medical Arts Health Research Group, Kelowna
Westview Research, North Vancouver
The Medical Arts Health Research Group, Penticton
Maritime Research Center, Bathurst
Source Unique Research, Hawkesbury
Gordon Schacter, MD, London
London East Medical Centre, London
SKDS Research Inc., Newmarket
University of Ottawa Health Services, Ottawa
London Road Diagnostic Clinic and Medical Centre, Sarnia
Kings County Medical Centre, Montague
Rhodin Recherche Clinique, Drummondville
Centre Medical Acadie, Montreal
Moscow Regional Scientific Research Clinical Institute named after M.F. Vladimirsky, Moscow
Moscow State Medico-Stomatological University, Moscow
"State Healthcare Institution City Clinical Hospital # 29", Moscow
State Healthcare Institution Moscow, Moscow
City Hospital # 31, Saint Petersburg
St. Petersburg City Hospital # 26, Saint Petersburg
St. Petersburg Pavlov State Medical University, Saint Petersburg
St. Petersburg Scientific-Research Institute of Pulmonology at State Medical University named after Academician I.P. Pavlov, Saint Petersburg
Lead Sponsor
Melinta Therapeutics, Inc.
INDUSTRY